Is Gvoke Approved for Type 2 Diabetics on Insulin?
Gvoke (glucagon injection) treats severe hypoglycemia in adults and children 2 years and older with diabetes, regardless of type 1 or type 2.[1] The FDA label explicitly covers type 2 diabetes patients, including those on insulin therapy, as insulin use increases hypoglycemia risk in both types.[2] Clinical studies supporting approval included type 2 patients on insulin regimens.[3]
How Does Gvoke Reverse Hypoglycemia in Type 2 Diabetics?
Gvoke is a ready-to-use nasal or auto-injector glucagon that raises blood glucose within 15 minutes by prompting liver glycogen breakdown.[1] It works independently of insulin—glucagon counters insulin's glucose-lowering effect. Type 2 patients on insulin (basal or mealtime) benefit if they experience severe lows unresponsive to oral carbs, common in intensive regimens.[4]
When Do Type 2 Insulin Users Need Gvoke Over Glucose Tablets?
Prescribe for severe hypoglycemia (unconsciousness, seizures, unable to swallow).[1] Type 2 patients on insulin face higher severe hypo risk with tight control or sulfonylureas.[5] Gvoke acts faster than oral glucose in emergencies; follow with carbs once alert.[2]
Limitations and Risks for Type 2 Patients
Not for mild hypoglycemia or non-diabetics. Type 2 patients with liver issues (e.g., fatty liver) may respond slower due to low glycogen stores.[1] Common side effects: nausea, vomiting (10-30%), headache.[3] No unique contraindications for type 2 on insulin, but train caregivers on use.[2]
Alternatives to Gvoke for Hypoglycemia Rescue